- June 16, 2026 - Now available directly to patients, MyPhenome is the first and only precision obesity test that goes beyond GLP-1 treatment response to help guide treatment decisions across a broad range of obesity therapies and interventions
Biopharma companies with GLP-1 (glucagon-like peptide-1) analogs, which have become a new trend in the obesity treatment market long dominated by appetite suppressants and fat-absorbance inhibitors, are upgrading their treatments
Maximizing Fat Loss with a Multifaceted Approach: Tesofensine, AOD9604, Retatrutide, Resistance Training, and High-Protein Nutrition Achieving sustainable fat loss while preserving muscle mass requires a strategic and multifaceted approach
Acylcarnitines (C8:0, C10:0, and C12:0) decreased in the CD+ group and neurovegetative symptoms of melancholia (NVSM+) group
The highest reported use concentration is 14.2% in lipsticks
10.1038/s41467-020-18249-3 Nat